Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
July 27 2020 - 8:00AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
second quarter of 2020 on Monday, August 3, 2020. The Company
will host a webcast and conference call that day at 8:30 a.m.
Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845
(domestic) or (765) 507-2618 (international) and referring to
conference ID number 8687621. A live webcast of the
conference call will be available online in the Investors and Media
section of the Company’s website at
ir.minervaneurosciences.com. The archived webcast will be
available on the Company’s website beginning approximately two
hours after the event for 30 days.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone
(MIN-101), in clinical development for schizophrenia; a potential
royalty stream from seltorexant (MIN-202 or JNJ-42847922), in
clinical development for insomnia and MDD; and MIN-301, in
pre-clinical development for Parkinson’s disease. Minerva’s common
stock is listed on the NASDAQ Global Market under the symbol
“NERV.” For more information, please visit
www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024